Skip to main content
Top
Published in: Journal of Neurology 6/2017

01-06-2017 | Neurological Update

Neuroborreliosis

Author: John J. Halperin

Published in: Journal of Neurology | Issue 6/2017

Login to get access

Abstract

Appropriate, critical application of evidence-based diagnostic criteria enables both a clear definition of what constitutes neuroborreliosis—nervous system infection with Borrelia burgdorferi sensu stricto in the US, B garinii and less commonly B. afzelii and other species in Europe—and recognition that this disorder is quite similar in Europe and the US. Most commonly evidenced by lymphocytic meningitis and/or multifocal inflammation of the peripheral (common; cranial neuropathy, radiculopathy, mononeuropathy multiplex) or central (rare) nervous system, it is readily diagnosed and highly antibiotic responsive. Encephalopathy—altered cognition or memory—can occur as part of the systemic infection and inflammatory state, but is not evidence of neuroborreliosis. Post treatment Lyme disease syndrome—persistent neurobehavioral symptoms 6 months or more after usually curative antibiotic treatment—if real and not simply an example of anchoring bias—is unrelated to neuroborreliosis. The pathophysiology of neuroborreliosis remains unclear, but appears to involve both a requirement for viable micro-organisms and significant immune amplification.
Literature
1.
go back to reference Garin C, Bujadoux A (1922) Paralysie par les tiques. J Med Lyon 71:765–767 Garin C, Bujadoux A (1922) Paralysie par les tiques. J Med Lyon 71:765–767
2.
go back to reference Halperin JJ, Krupp LB, Golightly MG, Volkman DJ (1990) Lyme borreliosis-associated encephalopathy. Neurology 40:1340–1343CrossRefPubMed Halperin JJ, Krupp LB, Golightly MG, Volkman DJ (1990) Lyme borreliosis-associated encephalopathy. Neurology 40:1340–1343CrossRefPubMed
3.
go back to reference Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ (2011) Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 53(6):541–547CrossRefPubMed Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ (2011) Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 53(6):541–547CrossRefPubMed
4.
go back to reference Wormser GP, Schriefer M, Aguero-Rosenfeld ME et al (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75(1):9–15CrossRefPubMed Wormser GP, Schriefer M, Aguero-Rosenfeld ME et al (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75(1):9–15CrossRefPubMed
5.
go back to reference Hansen K, Lebech AM (1992) The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 115:399–423CrossRefPubMed Hansen K, Lebech AM (1992) The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 115:399–423CrossRefPubMed
6.
go back to reference Stiernstedt GT, Granstrom M, Hederstedt B, Skoldenberg B (1985) Diagnosis of spirochetal meningitis by enzyme-linked immunosorbent assay and indirect immunofluorescence assay in serum and cerebrospinal fluid. J Clin Microbiol 21(5):819–825PubMedPubMedCentral Stiernstedt GT, Granstrom M, Hederstedt B, Skoldenberg B (1985) Diagnosis of spirochetal meningitis by enzyme-linked immunosorbent assay and indirect immunofluorescence assay in serum and cerebrospinal fluid. J Clin Microbiol 21(5):819–825PubMedPubMedCentral
7.
go back to reference Djukic M, Schmidt-Samoa C, Lange P et al (2012) Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 259(4):630–636CrossRefPubMed Djukic M, Schmidt-Samoa C, Lange P et al (2012) Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 259(4):630–636CrossRefPubMed
8.
go back to reference Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I (2010) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17(1):8–16 (e1–e4) Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I (2010) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17(1):8–16 (e1–e4)
9.
go back to reference Ogrinc K, Lusa L, Lotric-Furlan S et al (2016) Course and outcome of early European Lyme Neuroborreliosis (Bannwarth Syndrome): clinical and laboratory findings. Clin Infect Dis 63(3):346–353CrossRefPubMed Ogrinc K, Lusa L, Lotric-Furlan S et al (2016) Course and outcome of early European Lyme Neuroborreliosis (Bannwarth Syndrome): clinical and laboratory findings. Clin Infect Dis 63(3):346–353CrossRefPubMed
10.
go back to reference Rupprecht TA, Pfister HW, Angele B, Kastenbauer S, Wilske B, Koedel U (2005) The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65(3):448–450CrossRefPubMed Rupprecht TA, Pfister HW, Angele B, Kastenbauer S, Wilske B, Koedel U (2005) The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65(3):448–450CrossRefPubMed
11.
go back to reference Ljostad U, Mygland A (2008) CSF B–lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol 255(5):732–737CrossRefPubMed Ljostad U, Mygland A (2008) CSF B–lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol 255(5):732–737CrossRefPubMed
12.
go back to reference Gelderblom H, Londono D, Bai Y et al (2007) High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol 66(3):208–217CrossRefPubMed Gelderblom H, Londono D, Bai Y et al (2007) High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol 66(3):208–217CrossRefPubMed
13.
go back to reference Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA (2010) CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 37(5):283–287PubMedPubMedCentral Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA (2010) CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 37(5):283–287PubMedPubMedCentral
14.
go back to reference Kowarik MC, Cepok S, Sellner J et al (2012) CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 9:93CrossRefPubMedPubMedCentral Kowarik MC, Cepok S, Sellner J et al (2012) CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 9:93CrossRefPubMedPubMedCentral
15.
go back to reference Dersch R, Hottenrott T, Senel M et al (2015) The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. Fluids Barriers CNS 12(1):1–5CrossRef Dersch R, Hottenrott T, Senel M et al (2015) The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. Fluids Barriers CNS 12(1):1–5CrossRef
16.
go back to reference Halperin JJ, Luft BJ, Volkman DJ, Dattwyler RJ (1990) Lyme neuroborreliosis—peripheral nervous system manifestations. Brain 113:1207–1221CrossRefPubMed Halperin JJ, Luft BJ, Volkman DJ, Dattwyler RJ (1990) Lyme neuroborreliosis—peripheral nervous system manifestations. Brain 113:1207–1221CrossRefPubMed
17.
go back to reference England JD, Bohm RP, Roberts ED, Philipp MT (1997) Mononeuropathy multiplex in rhesus monkeys with chronic Lyme disease. Ann Neurol 41(3):375–384CrossRefPubMed England JD, Bohm RP, Roberts ED, Philipp MT (1997) Mononeuropathy multiplex in rhesus monkeys with chronic Lyme disease. Ann Neurol 41(3):375–384CrossRefPubMed
18.
go back to reference Kalina P, Decker A, Kornel E, Halperin JJ (2005) Lyme disease of the brainstem. Neuroradiology 47(12):903–907CrossRefPubMed Kalina P, Decker A, Kornel E, Halperin JJ (2005) Lyme disease of the brainstem. Neuroradiology 47(12):903–907CrossRefPubMed
19.
go back to reference Kan L, Sood SK, Maytal J (1998) Pseudotumor cerebri in Lyme disease: a case report and literature review. Pediatr Neurol 18(5):439–441CrossRefPubMed Kan L, Sood SK, Maytal J (1998) Pseudotumor cerebri in Lyme disease: a case report and literature review. Pediatr Neurol 18(5):439–441CrossRefPubMed
20.
go back to reference Castaldo JE, Griffith E, Monkowski DH (2008) Pseudotumor cerebri: early manifestation of adult Lyme disease. Am J Med 121(7):e5–e6CrossRefPubMed Castaldo JE, Griffith E, Monkowski DH (2008) Pseudotumor cerebri: early manifestation of adult Lyme disease. Am J Med 121(7):e5–e6CrossRefPubMed
21.
go back to reference Logigian EL, Kaplan RF, Steere AC (1990) Chronic neurologic manifestations of Lyme disease. N Engl J Med 323(21):1438–1444CrossRefPubMed Logigian EL, Kaplan RF, Steere AC (1990) Chronic neurologic manifestations of Lyme disease. N Engl J Med 323(21):1438–1444CrossRefPubMed
22.
go back to reference Halperin JJ, Volkman DJ, Wu P (1991) Central nervous system abnormalities in Lyme neuroborreliosis. Neurology 41:1571–1582CrossRefPubMed Halperin JJ, Volkman DJ, Wu P (1991) Central nervous system abnormalities in Lyme neuroborreliosis. Neurology 41:1571–1582CrossRefPubMed
23.
go back to reference Luo N, Johnson J, Shaw J, Feeny D, Coons S (2005) Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 43(11):1078–1086CrossRefPubMed Luo N, Johnson J, Shaw J, Feeny D, Coons S (2005) Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 43(11):1078–1086CrossRefPubMed
24.
go back to reference Klempner MS, Wormser GH, Wade K et al (2005) A case-control study to examine HLA haplotype associations in patients with posttreatment chronic Lyme disease. J Infect Dis 192(6):1010–1013CrossRefPubMed Klempner MS, Wormser GH, Wade K et al (2005) A case-control study to examine HLA haplotype associations in patients with posttreatment chronic Lyme disease. J Infect Dis 192(6):1010–1013CrossRefPubMed
25.
go back to reference Shadick NA, Phillips CB, Logigian EL et al (1994) The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med 121(8):560–567CrossRefPubMed Shadick NA, Phillips CB, Logigian EL et al (1994) The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med 121(8):560–567CrossRefPubMed
26.
go back to reference Klempner MS, Hu LT, Evans J et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345(2):85–92CrossRefPubMed Klempner MS, Hu LT, Evans J et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345(2):85–92CrossRefPubMed
27.
go back to reference Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60(12):1923–1930CrossRefPubMed Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60(12):1923–1930CrossRefPubMed
28.
go back to reference Fallon BA, Keilp JG, Corbera KM et al (2008) A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70:992–1003CrossRefPubMed Fallon BA, Keilp JG, Corbera KM et al (2008) A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70:992–1003CrossRefPubMed
29.
go back to reference Berende A, ter Hofstede HJ, Vos FJ et al (2016) Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med 374(13):1209–1220CrossRefPubMed Berende A, ter Hofstede HJ, Vos FJ et al (2016) Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med 374(13):1209–1220CrossRefPubMed
30.
go back to reference Ljostad U, Mygland A (2009) Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol 17(1):118–123CrossRefPubMed Ljostad U, Mygland A (2009) Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol 17(1):118–123CrossRefPubMed
31.
go back to reference Eikeland R, Mygland A, Herlofson K, Ljostad U (2013) Risk factors for a non-favorable outcome after treated European neuroborreliosis. Acta Neurol Scand 127(3):154–160CrossRefPubMed Eikeland R, Mygland A, Herlofson K, Ljostad U (2013) Risk factors for a non-favorable outcome after treated European neuroborreliosis. Acta Neurol Scand 127(3):154–160CrossRefPubMed
32.
go back to reference Dersch R, Sarnes AA, Maul M et al (2015) Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol 262(11):2572–2577CrossRefPubMed Dersch R, Sarnes AA, Maul M et al (2015) Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol 262(11):2572–2577CrossRefPubMed
33.
go back to reference Dersch R, Sommer H, Rauer S, Meerpohl JJ (2016) Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol 263(1):17–24CrossRefPubMed Dersch R, Sommer H, Rauer S, Meerpohl JJ (2016) Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol 263(1):17–24CrossRefPubMed
34.
go back to reference Wills AB, Spaulding AB, Adjemian J et al (2016) Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis 62(12):1546–1551CrossRefPubMedPubMedCentral Wills AB, Spaulding AB, Adjemian J et al (2016) Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis 62(12):1546–1551CrossRefPubMedPubMedCentral
35.
go back to reference Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (2000) Long-term outcomes of persons with Lyme disease. JAMA 283(5):609–616CrossRefPubMed Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (2000) Long-term outcomes of persons with Lyme disease. JAMA 283(5):609–616CrossRefPubMed
36.
go back to reference Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Nowakowski J (2015) Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. Am J Med 128(2):181–184CrossRefPubMed Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Nowakowski J (2015) Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. Am J Med 128(2):181–184CrossRefPubMed
37.
go back to reference Salazar JC, Gerber MA, Goff CW (1993) Long-term outcome of Lyme disease in children given early treatment. J Pediatr 122(4):591–593CrossRefPubMed Salazar JC, Gerber MA, Goff CW (1993) Long-term outcome of Lyme disease in children given early treatment. J Pediatr 122(4):591–593CrossRefPubMed
Metadata
Title
Neuroborreliosis
Author
John J. Halperin
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 6/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8346-2

Other articles of this Issue 6/2017

Journal of Neurology 6/2017 Go to the issue